Gilead Sciences Inc. has received approval from the U.S. Food and Drug Administration (FDA) for Yeztugo as PrEP to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg. This approval marks a significant step in HIV prevention efforts. Additionally, Gilead has submitted applications for marketing authorization and EU-M4all with the European Medicines Agency $(EMA)$ for the same medication, which are under expedited review. The company is also seeking regulatory approval for twice-yearly lenacapavir as PrEP in several countries, including Australia, Brazil, Canada, South Africa, and Switzerland, with plans for further filings in Argentina, Mexico, and Peru. This development aligns with Gilead's strategic partnership with The Global Fund to supply lenacapavir at no profit to reach up to two million people in supported countries over the next three years.